Authors

Latest:

Dr Carthon on Darolutamide Plus ADT in mHSPC

Bradley C. Carthon, MD, PhD, discusses treatment with darolutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer

Bradley Carthon, MD, PhD

Latest:

The Rapidly Changing Landscape in RCC Therapy: What Future Research May Hold

The poor long-term survival outcomes for patients with advanced renal cell carcinoma have prompted intensive clinical research aimed at developing novel therapeutic options addressing unmet needs.

Bradley G. Somer, MD

Latest:

Dr. Somer on the Impact of the IMbrave150 Trial on the HCC Paradigm

Bradley G. Somer, MD, discusses the impact of the phase 3 IMbrave150 trial on the treatment of patients with unresectable hepatocellular carcinoma.

Bradley J. Monk, MD, Creighton University School of Medicine

Latest:

Dr. Monk on the Utility of Tisotumab Vedotin in Recurrent Cervical Cancer

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of tisotumab vedotin in recurrent cervical cancer.

Bradley J. Monk, MD, Creighton University School of Medicine

Bradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology

Latest:

Practical Implications for Treatment Strategies in Advanced Ovarian Cancer

Bradley J. Monk, MD, FACOG, FACS, University of Arizona

Latest:

Heterogeneity of Endometrial Cancer

Experts in gynecologic cancer discuss the heterogeneity of endometrial cancer..

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

Latest:

Dr. Monk on Potential Shifts to Treatment Sequencing Strategies in Cervical Cancer

Bradley J. Monk, MD, FACS, FACOG, discusses potential shifts to treatment sequencing strategies in cervical cancer.

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology Practice of US Oncology

Bradley J. Monk, MD, FACS, FACOG, The University of Arizona College of Medicine

Bradley J. Monk, MD, FACS, FACOG, University of Arizona

Latest:

Biomarker Testing and Multidisciplinary Approaches in EC

Key opinion leaders share their thoughts on biomarker testing and multidisciplinary approaches for endometrial cancer at their institutions globally.

Bradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology

Latest:

The Future of Endometrial Cancer Treatment

Experts give insight on what they are looking forward to in the endometrial cancer space.

Bradley J. Monk, MD, University of Arizona

Bradley J. Monk, MD, University of Arizona Cancer Center

Bradley McGregor, MD

Latest:

Dr McGregor on Future Biomarker Analyses With Nivolumab Plus Ipilimumab in Bladder Cancer

Bradley McGregor, MD, discusses next steps for research with ipilimumab plus nivolumab for patients with diverse bladder cancer histologies.

Bradley McGregor, MD, Dana-Farber Cancer Institute

Latest:

Series Wrap-up: Novel Therapies for mRCC

A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.

Bradley Monk, MD, FACOG, FACS, St. Joseph's Hospital

Brady L. Stein, MD

Latest:

Dr. Stein Discusses Changes to the NCCN Guidelines in MPNs

Brady L. Stein, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses changes to the National Comprehensive Cancer Network (NCCN) guidelines in myeloproliferative neoplasms (MPNs).

Brandon G. Smaglo, MD, FACP

Brandon G. Smaglo, MD, FACP, is an associate professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Latest:

Dr Smaglo on Selecting Between Frontline Chemotherapy Regimens for Pancreatic Cancer

Brandon G. Smaglo, MD, FACP, discusses considerations for choosing between frontline chemotherapy-based regimens for patients with pancreatic cancer.

Brandon Huffman, MD

Latest:

Dr Huffman on the Investigation of Azenosertib Plus Gemcitabine in Advanced Pancreatic Cancer

Brandon Huffman, MD, discusses an ongoing phase 2 trial evaluating azenosertib plus gemcitabine in advanced pancreatic cancer.